News | Heart Failure | June 30, 2020

BioCardia Resumes Cases in the CardiAMP Heart Failure Trial

BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era

BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era

June 30, 2020 —  BioCardia, Inc. announced that the company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. New consents have also taken place at additional centers. 

“We are pleased to be able to resume enrollment at several sites for our lead clinical program and look forward to cases taking place in July and August,” said BioCardia CEO Peter Altman, Ph.D. “As study centers resume elective procedures, we are working closely with our clinical partners to implement new FDA recommendations for clinical trials with respect to COVID-19 in order to minimize the impact on our patients, as well as the trial ahead. COVID-19 has been reported to cause heart damage, and some of our clinical investigators are seeing an increased amount of heart damage in patients who have avoided treatment due to fear of COVID-19 exposure. Our cardiac programs have the potential to help address this growing clinical need and are even more important in the current clinical landscape.”

The CardiAMP Heart Failure Trial is studying CardiAMP cell therapy, an autologous bone marrow-derived mononuclear cell formulation designed to stimulate the body’s natural healing response in treating heart failure which develops after a heart attack. The trial is evaluating the cell therapy’s ability to improve patient survival, exercise capacity and quality of life, as well as its safety. The CardiAMP Heart Failure Trial is the first multicenter clinical trial of an autologous cell therapy to prospectively select patients based on cell potency to maximize the probability of patient benefit.

The ongoing multi-center, double-blinded, randomized (3:2), controlled pivotal CardiAMP Heart Failure Trial is expected to enroll 260 patients at up to 40 centers nationwide. The national co-principal investigators are Amish Raval, M.D., of the University of Wisconsin and Carl Pepine, M.D., of the University of Florida, Gainesville.

In March 2020, the Data Safety Monitoring Board indicated there were no safety concerns with the CardiAMP study results and recommended that the trial continue, as planned. To date, 75 patients have been enrolled at 25 active centers. The trial is sponsored, in part, by the Maryland Stem Cell Research Foundation and has reimbursement from the Centers for Medicare and Medicaid Services (CMS). 

For more information: www.biocardia.com

Related CardiAMP Heart Failure Trial content:

How Biotechnology is Impacting the Treatment and Prevention of Heart Disease

CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium

BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial

 

Related Content

Rates of burnout pre- and peak COVID-19 pandemic increased across all members of the cardiology care team and was particularly striking among cardiovascular team members, which researchers said may be because they were more likely at the bedside as patients were dying. Among all cardiovascular clinicians – cardiologists, physician assistants, nurse practitioners, nurses, pharmacists and imaging technologists – half provided direct care to patients with COVID-19. #COVID19 #ACCCOVID

Rates of burnout pre- and peak COVID-19 pandemic increased across all members of the cardiology care team and was particularly striking among cardiovascular team members, which researchers said may be because they were more likely at the bedside as patients were dying. Among all cardiovascular clinicians – cardiologists, physician assistants, nurse practitioners, nurses, pharmacists and imaging technologists – half provided direct care to patients with COVID-19, and yet one of five reported not having adequate personal protective equipment (PPE). Not surprisingly, the rate of burnout was higher in this group. Getty Images
 

News | Coronavirus (COVID-19) | June 07, 2021
June 7, 2021 — The COVID-19 pandemic has taken a significant toll on cardiovascular clinicians, many of whom provide
U.S. positive COVID test case data for 2020 through June 3, 2021, It shows four clear waves of spikes in U.S. COVID cases. Most of these appeared to be partly fueled by people gathering during the July 4, Halloween, Thanksgiving, Christmas, New Year's, Valentine's Day, and easter holidays. Source: John Hopkins University

U.S. positive COVID test case data for 2020 through June 3, 2021, It shows four clear waves of spikes in U.S. COVID cases. Most of these appeared to be partly fueled by people gathering during the July 4, Halloween, Thanksgiving, Christmas, New Year's, Valentine's Day, and easter holidays. Source: Johns Hopkins University

News | Coronavirus (COVID-19) | June 04, 2021 | By Dave Fornell, Editor
Vaccinations appear to to be helping reduce...
MRI scan of heart damaged by COVID, which can cause myocarditis, infarction and/or ischemia. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Image courtesy of European Heart Journal

MRI scan of heart damaged by COVID, which can cause myocarditis, infarction and/or ischemia. Blue means reduced blood flow, orange is good blood flow. In this figure the inferior part of the heart shows dark blue, so the myocardial blood flow is very reduced. The angiogram shows the coronary artery which supplies the blood to this part of the heart is occluded. The three colored MRI images show different slices of the heart — the basal mid and apical slices. Read more. Image courtesy of European Heart Journal

News | Coronavirus (COVID-19) | June 03, 2021
DAIC's sister radiology magazine Imaging Technology News (ITN) has created a photo gallery that sho
The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams. #ACC21 #ACC2021

The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams.

Feature | Coronavirus (COVID-19) | May 18, 2021
May 18, 2021 — Artificial intelligence (AI) derived heart measurements were able to predict...
Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21. #ACC #ACC21 #ACC2021

Dapagliflozin did not significantly reduce organ failure or death in high-risk hospitalized COVID-19 patients in the DARE-19 trial results, presented at ACC.21.

News | Coronavirus (COVID-19) | May 18, 2021
May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly re
According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

According to the CDC, if you are fully vaccinated you can start doing many things that you had stopped doing because of the pandemic. Infographic courtesy of the CDC.

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — The Centers for Disease Control and Prevention (CDC) just
Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19

Getty Images

News | Coronavirus (COVID-19) | May 13, 2021
May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the
One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infarction (STEMI), according to the latest, comprehensive data from The North American COVID-19 Myocardial Infarction (NACMI) Registry. The data was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. The study showed there was an alarming one-in-three patients dying with STEMI and COVID, compared to 4-in-100 #SCAI2021

The key slide from the SCAI 2021 NACMI late-breaking presentation showing the very high adverse rates for COVID STEMI heart attack patients (red) as compared to pre-pandemic STEMI patient controls (green).

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
May 3, 2021 – One third of patients will die who have COVID-19 (SARS-CoV-2) and suffer a ST-elevated myocardial infar
CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 13, 2021 | By Dave Fornell, Editor
(This story was updated May 7, 2021 in the last subheaded section)